Education
About Us
Working with TipRanks
Follow Us
Acutus Medical (AFIB)
OTHER OTC:AFIB
Top Page
Acutus Medical
(OTC:AFIB)
43Neutral
Acutus Medical (AFIB) vs. S&P 500 (SPY)
Market Cap
$1.28M
Dividend YieldN/A
Average Volume (3M)28.92K
Price to Earnings (P/E)―
Beta (1Y)-0.01
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees85
SectorHealthcare
Sector Strength65
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.32
Shares Outstanding29,912,306
10 Day Avg. Volume20,348
30 Day Avg. Volume28,917
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.25
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Acutus Medical Business Overview & Revenue Model
Company DescriptionAcutus Medical, Inc. (AFIB) is a medical technology company that specializes in the development and commercialization of innovative solutions designed to improve the treatment of complex cardiac arrhythmias. Operating primarily in the healthcare sector, Acutus Medical focuses on providing electrophysiologists with advanced tools and technologies, such as its AcQMap system, which offers a comprehensive approach to mapping and treating atrial fibrillation and other arrhythmias.
How the Company Makes MoneyAcutus Medical generates revenue through the sale and leasing of its medical devices, primarily the AcQMap system. The company's revenue model includes direct sales to hospitals and healthcare facilities, as well as partnerships with distributors and strategic alliances that enable broader market penetration. Acutus may also derive income from recurring revenue streams such as disposables and accessories associated with its mapping and treatment systems. Additionally, the company could benefit from collaborations with research institutions and other entities focused on advancing cardiac care technologies.
Acutus Medical Financial Statement Overview
Summary
Acutus Medical faces substantial financial challenges, characterized by declining revenues, high leverage, negative equity, and poor cash flow generation. The company's financial health is concerning, with ongoing losses and limited growth prospects.Income Statement
Acutus Medical's revenue has declined significantly over the years, with a negative net income and consistently poor profit margins. The gross profit margin is slightly positive in the latest TTM, but the net profit margin remains negative, indicating ongoing profitability challenges.20
Very Negative
Balance Sheet
The company's balance sheet is weak, with negative stockholders' equity and a high debt-to-equity ratio, reflecting significant leverage. The equity ratio is unfavorable, indicating potential financial instability.15
Very Negative
Cash Flow
Acutus Medical shows negative free cash flow and operating cash flow, although there's a reduction in free cash flow negativity in the latest TTM. The company struggles with cash generation relative to its net income.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 5.49M | 7.16M | 16.36M | 17.26M | 8.46M | 2.84M | Gross Profit |
| 5.61M | -3.14M | -15.55M | -15.66M | -7.42M | -6.41M | EBIT |
| 35.90M | -14.36M | -27.34M | -112.12M | -91.33M | -72.57M | EBITDA |
| 34.35M | -13.49M | 35.20M | -105.12M | -91.33M | -68.12M | Net Income Common Stockholders |
| -41.91M | -81.66M | -39.62M | -123.36M | -101.98M | -119.31M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 17.75M | 22.40M | 70.45M | 100.77M | 131.07M | 71.80M | Total Assets |
| 0.00 | 53.96M | 133.44M | 169.79M | 192.53M | 105.45M | Total Debt |
| 0.00 | 38.48M | 38.86M | 45.40M | 41.08M | 41.13M | Net Debt |
| 0.00 | 19.31M | 13.27M | 21.33M | 15.84M | 31.68M | Total Liabilities |
| 0.00 | 54.84M | 58.42M | 64.07M | 65.95M | 331.27M | Stockholders Equity |
| 0.00 | -879.00K | 75.02M | 105.73M | 126.58M | -225.81M |
| Cash Flow | Free Cash Flow | ||||
| -44.59M | -63.34M | -89.02M | -109.66M | -96.39M | -69.38M | Operating Cash Flow |
| -45.62M | -63.12M | -85.03M | -99.68M | -85.17M | -55.99M | Investing Cash Flow |
| 27.90M | 58.55M | 104.75M | 19.07M | -63.82M | -70.43M | Financing Cash Flow |
| -3.16M | -2.66M | -12.12M | 79.57M | 164.43M | 126.34M |
Acutus Medical Technical Analysis
Negative
0.04
Price Trends
0.05
Negative
0.06
Negative
0.06
Negative
Market Momentum
>-0.01
Negative
40.37
Neutral
42.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AFIB, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.37 is Neutral, neither overbought nor oversold. The STOCH value of 42.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AFIB.
Acutus Medical Risk Analysis
Acutus Medical disclosed 63 risk factors in its most recent earnings report. Acutus Medical reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acutus Medical Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $3.30B | ― | -75.27% | ― | 20.13% | 10.05% | |
59 Neutral | $151.32M | ― | -144.19% | ― | 0.55% | -8.47% | |
51 Neutral | $267.83M | ― | -55.25% | ― | 22.01% | 10.02% | |
48 Neutral | $6.86B | 1.11 | -51.04% | 2.47% | 16.66% | 1.53% | |
43 Neutral | $1.28M | ― | 406.89% | ― | ― | ― | |
43 Neutral | $1.96B | ― | -46.67% | ― | 18.82% | 19.76% | |
36 Underperform | $18.08M | ― | -154.54% | ― | ― | 66.72% |
* Healthcare Sector Average
Performance Comparison
AFIB
Acutus Medical
0.04
-0.14
-77.78%
STXS
Stereotaxis
1.71
-1.30
-43.19%
NVCR
NovoCure
17.52
3.13
21.75%
IRTC
Irhythm Technologies
106.88
-2.37
-2.17%
BIVI
BioVie
0.84
-4.41
-84.00%
LUNG
Pulmonx
6.87
-1.64
-19.27%
Acutus Medical Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Acutus Medical Restructures Workforce Amid Strategic Shift
Negative
Dec 4, 2024
Acutus Medical has announced a significant downsizing, reducing its workforce by 70% to focus solely on fulfilling obligations to Medtronic for left-heart access products. This strategic move aims to cut costs while leveraging potential earnout payments from Medtronic until 2027. The transition will include operational changes and a shift in CEO and CFO roles, with the company continuing to support Medtronic through contract manufacturing. The downsizing is expected to be largely complete by Q1 2025.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.